The insulin receptor is a dimeric protein that has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels 1,2 . Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease 1,3,4 . The primary sequence of the receptor has been known since the 1980s 5 , and is composed of an extracellular portion (the ectodomain, ECD), a single transmembrane helix and an intracellular tyrosine kinase domain. Binding of insulin to the dimeric ECD triggers autophosphorylation of the tyrosine kinase domain and subsequent activation of downstream signalling molecules. Biochemical and mutagenesis data have identified two putative insulin-binding sites, S1 and S2 6 . The structures of insulin bound to an ECD fragment containing S1 and of the apo ectodomain have previously been reported 7,8 , but details of insulin binding to the full receptor and the signal propagation mechanism are still not understood. Here we report single-particle cryo-electron microscopy reconstructions of the 1:2 (4.3 Å) and 1:1 (7.4 Å) complexes of the insulin receptor ECD dimer with insulin. The symmetrical 4.3 Å structure shows two insulin molecules per dimer, each bound between the leucinerich subdomain L1 of one monomer and the first fibronectin-like domain (FnIII-1) of the other monomer, and making extensive interactions with the α-subunit C-terminal helix (α-CT helix). The 7.4 Å structure has only one similarly bound insulin per receptor dimer. The structures confirm the binding interactions at S1 and define the full S2 binding site. These insulin receptor states suggest that recruitment of the α-CT helix upon binding of the first insulin changes the relative subdomain orientations and triggers downstream signal propagation.
(α β ) heterodimer as the insulin receptor monomer, and to the (α β ) 2 tetramer as the insulin receptor dimer.
Current models of insulin binding to the insulin receptor suggest that there are two interaction sites on insulin that engage with two binding sites (S1 and S2) on the receptor 11 . Binding is thought to occur in trans, with each insulin molecule interacting with S1 of one insulin receptor monomer and S2 of the other monomer. The bridging of these receptor binding sites constitutes the high-affinity interactions, whereas lowaffinity interactions arise from single-site occupancy. The high-affinity interaction has a K d of 6-200 pM for the solubilized and affinitypurified full-length receptor, whereas the low-affinity interactions have K d values of 6 nM (for S1) and 400 nM (for S2) 12 . Upon insulin binding to the full-length receptor, there are multiple binding events and dissociations and/or multiple rearrangements within low-and high-affinity binding poses 12 . Receptor activation is caused by high-affinity binding; however, the activation curve is complex and shows anti-cooperative binding 13 .
Here we report the 4.3 Å resolution structure of the insulin receptor ECD in the presence of insulin, obtained using single-particle cryo-electron microscopy (cryo-EM) (Fig. 1b, c) . A pronounced preferred orientation of the complex in vitreous ice was overcome with a combination of tilted data collection 14 and fast plunge speeds using the Spotiton instrument 15, 16 . Further details are provided in the Methods. Three-dimensional classification of the cryo-EM data identified a dimeric structure with two populations, in an approximately 4:1 ratio (Fig. 2, Extended Data Fig. 1 ). The larger of these populations, class 1, is characterized by a symmetrical 'head' and a poorly resolved, apparently flexible 'stalk' . Refinement of the class 1 structure, after masking out flexible portions of the stalk and applying C2 symmetry, provided a reconstruction to 4.3 Å (Extended Data Figs 1, 2). The electron density map enabled unambiguous identification of the L1, CR, L2 and FnIII-1 receptor domains, as well as the clear positioning of the insulin molecule and the α -CT helix (Fig. 1b, c) . Refinement of the data using C1 symmetry produced a lower resolution map (4.7 Å; Extended Data Fig. 3 ) in which additional density, assigned to FnIII-2, was visible for one monomer (Extended Data Figs 4a, 5b) .
The class 1 structure shows two insulin molecules, symmetrically bound, per dimeric receptor. Although asymmetric binding was predicted for the full-length receptor 12 , studies show that the soluble ECD binds two molecules of insulin, each with a K d of 3.5 nM and a fast dissociation rate 17 . The symmetrical binding of both insulin molecules observed in the cryo-EM map is consistent with these data. Each insulin molecule is located between the L1 domain of one receptor monomer, the FnIII-1 domain of the other monomer, and the α -CT helix (Fig. 1c ). Residues of the L1 subdomain and the α -CT helix, previously identified biochemically as essential for insulin binding 13 , have been hypothesized to represent the S1 site 18 . Structures of 'S1 microreceptors' (containing L1, CR and a portion of the α -CT) in complex with insulin or insulin mimetics 7 provided the first atomic details of some key insulin receptorinsulin interactions (Extended Data Table 1 ). In these structures, insulin interacts directly with the L1 subdomain of the receptor through only a small region of the B helix, and most of the other residues in the receptor that have been identified as essential for insulin binding (Extended Data  Table 1 ) interact with the α -CT helix. Predicted interactions involving the C-terminal end of the insulin β-chain 6 were also structurally visualized (Extended Data Table 1 ). The cryo-EM structure confirms the engagement of S1, including the interactions involving the C terminus of the insulin β -chain, which is now resolved. The C-terminal region of the β -chain in the bound form assumes a different conformation from that observed in the insulin-free form (for example, Protein Data Base (PDB) ID: 1ZNI; Extended Data Fig. 4c ), allowing the β -chain core residues Gly8-Cys19 to interact with the α -CT helix, confirming the so-called detachment model of insulin binding 19 . Although it is not possible to determine which receptor monomer each α -CT helix originates from using the current map, the fact that each insulin molecule interacts with residues belonging to both monomers supports the trans-binding-mode hypothesis.
Analysis of the cryo-EM structure shows that S2 (Extended Data  Table 1 ) is defined by interactions between the insulin receptor sequences Pro495-Arg498 and Arg539-Asn541 (located within the FnIII-1 domain) and chain B of insulin (residues Gln4-Gly8 and His10). Earlier work suggested that these insulin residues interacted with the S2 binding site 6 , but no partner residues were assigned on the receptor. The present structure shows interactions between the α -CT helix residues Leu696-Lys703 and insulin receptor residues Gly346-Asn349 and Arg372-Tyr374 (in the L2 subdomain) and Arg498-Leu501 and Val570-Thr571 (in the FnIII-1 subdomain). Previous work had correctly predicted that residues in L2 and FnIII-1 make up the S2 site 20 . Clinical mutations (S323L, F382V, K460E and N462S, all located within or near the L2 and FnIII-1 subdomains discussed above) result in impaired insulin binding or reduced signalling [21] [22] [23] [24] . Further evidence that these regions represent S2 comes from ref. 25 , in which a truncated receptor formed from the L1, CR, L2 and FnIII-1 subdomains fused to the α -CT helix was shown to have insulin-binding properties that are identical to those of the full ECD. A second possible location for the S2 site (at the junction of the FnIII-1 and FnIII-2 domains) was hypothesized from the crystallographic structure of the insulin-free insulin receptor ECD dimer 8 . Mutagenesis data provided some support for this assignment 11 ; however, in the un-symmetrized map (Extended Data Figs 4a, 5b) in which the FnIII-2 is visible, the bound insulin is more than 50 Å from this predicted S2 site (Extended Data Fig. 4b ), on the opposite side of the receptor.
Refinement of the structural data for the smaller class 2 produced a 7.4 Å map ( Fig. 2 , Extended Data Figs 1, 6). In this map, half of the 'head' has an overall conformation similar to that observed in the class 1 map, with visible densities for the α -CT helix and insulin. The other half showed the L1-CR-L2 portion in a different conformation ( Fig. 2a ): more open, and characterized by less-well-defined density. The model of the insulin receptor based on the class 1 structure was rigid-body fitted onto the class 2 map, and only one insulin molecule and one α -CT helix were included in the final structure. The open side lacked both the insulin and the helix (Fig. 2b ). This conformation therefore comprises both an insulin-bound receptor monomer and an insulin-free receptor monomer. Comparison of these structures suggests that insulin binding induces both the closing of the top portion of the receptor (by rigid-body motion of the L1-CR-L2 portion with respect to the FnIII-1 domain) and recruitment of the α -CT helix, contrary to a previously suggested mechanism in which insulin docks to a preformed 'harbour' containing both the L1 and α -CT elements that are required for binding 26 .
The insulin receptor dimer identified in the cryo-EM analysis does not resemble the crystallographic symmetry-generated dimer 8 . The relative arrangement of the two monomers differs between the cryo-EM and crystallographic dimers, and transitioning between them would require major conformational changes and disruption of extensive surface interfaces, specifically the interactions between L1 and FnIII-2′ and their dimeric symmetry mates, and between L2, FnIII-1′ and their dimeric symmetry mates ( Fig. 3a and Extended Data Fig. 7 ). However, the overall conformation of the crystallographic monomer (PDB ID: 4ZXB) is similar to that of the unbound monomer observed in the class 2 cryo-EM structure ( Fig. 3b ), suggesting that it could be a biologically relevant representation of the unbound insulin receptor monomer. Attempts to obtain a cryo-EM reconstruction for the ECD in the absence of insulin (the apo state) proved unsuccessful as the particles showed a high degree of heterogeneity and many were smaller than expected, suggesting that the ECD dimer may be unstable in the absence of the ligand. Comparing the unbound monomer from the crystal structure to the insulin-bound monomer from the cryo-EM structure (Extended Data Fig. 8 ), it appears that the conformational change that occurs upon insulin binding can be described as two rotations. The first is a 35° rotation of the L2-CR-L1 domains with Letter reSeArCH
respect to the linker connecting the L2 and FnIII-1 domains (residues Ala466-E469); the second is a 55° swing of the CR-L1 pair (as a rigid body) around the Gly306-Lys310 linker between the CR and L2 domains (not resolved in the current structure). These domain movements are similar to the rotation and translation observed upon ligand binding in the related EGFR family 27 . On the basis of the comparison between unbound and bound receptors, it appears that the α -CT helix moves between approximately 55 Å (if we consider the helix from the same monomer) and approximately 70 Å (if we consider the α -CT from the other monomer). Figure 3c shows a schematic of a possible mechanism for insulin receptor transduction. It is likely that, following the binding of the first insulin molecule, the large shift in the position of the α -CT helix causes conformational changes in the insertion domain (ID)-α of both monomers. ID-α is disulfide bonded to FnIII-3 (Cys647-Cys860) and this connection (the 'signalling bridge' 26 ) may induce further conformational changes in the FnIII-3 domain, thus triggering the downstream signal propagation.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
T K TK TK TK T K Figure 3 | Proposed transduction mechanism. a, Comparison between the cryo-EM (insulin bound) and the crystallographic (apo) dimers. Both dimers are shown as surface representation of the coordinates. Similar conformational differences between unbound and insulin-bound insulin receptor have been reported 30 . b, Side and top views of the monomer (PDB ID: 4ZXB) overlaid onto the cryo-EM 'open' monomer using the FnIII-1 domain. c, Schematic of a possible activation mechanism for the insulin receptor. The insulin receptor subdomains, colour coded as in Fig. 1a (solid colours for the α -chain and lighter colours with thicker outer lines for the β -chain). Dotted lines, inter-monomer disulfide bonds; solid orange line, the signalling bridge 26 . Binding of one insulin molecule to the apo receptor (left to middle panel) causes the L1-CR-L2 subdomains of one monomer, the FnIII-1 subdomain of the other and the α -CT helix to move to generate the binding site. The movement of the α -CT helix and the attached ID-α causes, via the signalling bridge, a conformational change in the FnIII-3 domain. Because the two ID-α regions are also disulfide bonded, the movement of one is likely to be transmitted to the other, inducing a similar conformational change in the other FnIII-3 domain. These changes propagate through the transmembrane helix to the tyrosine kinase domains, inducing autophosphorylation and activation of the signalling pathway. This state is seen in the cryo-EM class 2 map. Right, binding of a second insulin molecule recruits the second α -CT (cryo-EM class 1 map) and may fully stabilize the activated complex. Although the diagram suggests that the α -CT helix involved in insulin binding is the one from the same monomer (cis interaction), there is no evidence, to our knowledge, that rules out a trans interaction.
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Recombinant proteins. Recombinant human insulin receptor-CD220 (R&D systems, 1544-IR-50/CF) was reconstituted in PBS pH 7.4 at 0.3 mg/ml (0.00293 mM), stored in 100-μ l aliquots at − 80 °C and used without further purification. The protein was tested for insulin binding using 125 I-insulin competition and surface plasmon resonance (Extended Data Table 2 ). The measured binding potency and binding affinities were consistent with values from the literature 17, 31 . A Coomassie-stained SDS-PAGE gel (Extended Data Fig. 5 ) of the sample shows the expected bands for the α -and β -chains. The apparent molecular weights of both chains were higher than predicted (82.9 kDa for the α -subunit and 22.9 kDa for the β -subunit), and the β -subunit appears as three discrete bands. This has previously been observed 17, 32, 33 and can be attributed to glycosylation (and to different states of glycosylation for the β subunit). The gel confirms the integrity of the sample used in the studies.
Recombinant human insulin (RHI) was obtained from the laboratories of Merck. RHI is a commercially available material; a generic version of the bioprocess used in preparing it has been described 34 . A stock solution (5.6 mg/ml, 0.969 mM) was made in HBS (10 mM Hepes pH 7.4, 150 mM NaCl) and stored at 4 °C. Insulin receptor ECD competition binding assay. Purified His-tagged human insulin receptor ECD (R&D Systems) was bound to an anti-mouse IgG coated microplate via attachment to a mouse monoclonal anti-human insulin receptor capture antibody (R&D Systems). Varying concentrations of RHI were incubated with the insulin receptor ECD in the presence of 0.1 nM 125 I-insulin (PerkinElmer, catalogue NEX420050UC) overnight at 4 °C in binding buffer (100 mM HEPES, 100 mM NaCl, 10 mM MgCl 2 , 0.02% Triton X-100, pH 8). Plate washings with binding buffer were carried out after the antibody and protein capture steps and following ligand incubation. The amount of radioligand still bound to the insulin receptor ECD was determined with either a TopCount or a MicroBeta instrument using Microscint-40. Concentration response curves were generated and IC 50 values were calculated using a four-parameter fit. Insulin receptor ECD direct binding assay. Purified His-tagged human insulin receptor ECD (R&D Systems) was immobilized to a Biacore CM5 chip via an anti-His antibody kit (GE Healthcare Life Sciences) following the manufacturer's instructions. RHI binding to the immobilized human insulin receptor ECD was assayed by passing varying RHI concentrations in running buffer (1× HBS-EP; 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% P-20, pH 7.3) over the chip. General detection and data collection parameters for the Biacore T200 instrument were used to determine k on , k off and K d values. Grid preparation. Samples for grid preparation were generated by mixing 100 μ l insulin receptor solution and 3 μ l insulin stock (for a final insulin receptor:insulin ratio of 1:10) followed by incubating on ice for at least one hour before making vitrified grids. Poor grid reproducibility and difficulty in obtaining suitable ice thickness presented issues when using manual grid preparation. To address these issues, the samples were vitrified using a semi-automated Spotiton V1.0 robot 15, 16, 35 , a device for preparing cryo-EM samples that uses piezo-electric dispensing to apply small (50-pl) drops of sample across a 'self-blotting' nanowire grid as it flies past en route to plunging into liquid ethane. The nanowire grids, manufactured in house, used either lacey carbon or lacey gold supports 36 ; the gold supports help to optimize image quality when acquiring data with the grid tilted relative to the electron beam 14, 37 . Tilted data collection was necessary to address highly preferred particle orientation observed during initial data collections. For the tilted datasets, nanowire gold substrate grids were plasma cleaned for 10 s (with O 2 and H 2 ). The sample was dispensed onto these grids in 50-pl drops for a total of ~ 5 nl sample dispensed in a stripe from top to bottom across each grid, before the grid was plunged into liquid ethane. The time between sample application to the grid and the plunge into ethane was typically ~ 300 ms. Subsequently, we modified the SpotItOn instrument to further reduce the time between sample application and plunge to ~ 170 ms. This modification was undertaken in an attempt to reduce the time the sample has to interact with the air-water interfaces in the thin liquid film before vitrification. These interactions are assumed to be the cause of preferred particle orientations 38 , and indeed the faster plunging speed resulted in grids that displayed markedly better particle distribution (data not shown), enabling the collection of data at zero-degree tilt. Nanowire-based, self-blotting grids with a lacey carbon supporting substrate were used for this purpose, following the same sample preparation methods described above. Data collection and processing. Tilted data were collected on a Titan Krios (Thermo Fisher) equipped with an energy filter and a Gatan K2 Counting camera. The microscope was operated at 300 kV and a nominal magnification of 105,000× , with a calibrated pixel size of 1.1 Å. The defocus ranged from − 1 to − 2.5 μ m. Images were collected at a tilt angle of − 30° to address the issue of preferred orientation identified during initial data collection 14 . Exposure was set to 10 s (40 frames per image), for a total dose of ~ 68 e − Å −2 . A total of 6,805 images was collected in three sessions using Leginon 39 . Of these, 3,056 images were selected as suitable for further data processing. Frames were aligned using MotionCor2 40 ; global and per-particle CTF was calculated using gCTF 41 . Particle picking was done using Gautomatch (http://www.mrc-lmb.cam.ac.uk/kzhang/) and resulted in 1,206,222 particles. All subsequent data processing (from 2D classification to final reconstruction) was done using Cryosparc 42 . After several cycles of 3D classification, 151,409 particles in one class were used to generate a 4.6 Å map with C2 symmetry (and a 5.6 Å map with C1 symmetry). A C1 symmetry map was generated at 7.4 Å resolution from 48,315 particles in a second class (Extended Data Fig. 1) . Fewer than 20% of the originally selected particles contributed to the final 3D maps. This was caused firstly by very liberal initial picking criteria that resulted in a high rate of false positives that were rejected during initial 2D classification (approximately 60%). Secondly, there is a possibility that a substantial fraction of the receptor is not complexed, or alternatively, that there is a fast equilibrium between bound and unbound species that shows up as heterogeneity, limiting the contribution of these particle to the 3D structure.
Untilted data were collected on a Titan Krios (Thermo Fisher) equipped with an energy filter and a Gatan K2 Counting camera. The microscope was operated at 300 kV and a nominal magnification of 105,000× , with a calibrated pixel size of 1.1 Å. The defocus ranged from − 1 to − 2.5 μ m. Exposure was set to 10 s (40 frames per image), for a total dose of ~ 66 e − Å −2 . A total of 2,487 images was collected in three sessions using Leginon 39 . Of these, 1,526 images were selected as suitable for further data processing. Frames were aligned using MotionCor2 40 ; global and per-particle CTF was calculated using gCTF 41 . Particle picking was done using Gautomatch (http://www.mrc-lmb.cam.ac.uk/kzhang/) and produced 348,930 particles. All subsequent data processing (from 2D classification to final reconstruction) was done using Cryosparc 42 . After several cycles of 3D classification, a set of 40,390 particles was identified, which produced a 4.7 Å class 1 map after symmetrized homogeneous refinement. This set was merged with the 151,409 particles from the tilted class 1 set. After a round of heterogeneous refinement, 147,436 particles were used to generate a 4.3 Å map with C2 symmetry (and a 4.7 Å map with C1 symmetry) (Extended Data Fig. 1 ). The resolution of each reconstruction was determined by the gold standard Fourier shell correlation (FSC) criterion in Cryosparc 42 and RELION PostProcess 43 . The completeness of the maps was assessed by measuring the Euler angle orientation distribution (as calculated by Cryosparc 42 ) and by evaluating the 3D FSC 14 of each map. (Extended Data  Figs 2, 3, 6 ). The quality of the map was confirmed by the ability to see separated β -strands and the presence of bulky side chains (Extended Data Fig. 2f ). Structure solution. Individual domains of the insulin receptor (L1, CR, L2 and FnIII-1, from PDB ID: 4XZB) were positioned into the initial 4.6 Å resolution map using Molrep 44 and rigid-body refined using Coot 45 . The insulin and the α -CT helix were positioned by overlaying the microreceptor structure from PDB ID 3W11 9 onto the L1 domain of the complex and rigid body fitting them into the available density. The α -CT helix was manually extended, while the full insulin molecule was built using as a reference one of the monomers from PDB ID 1ZNI. The full structure was subjected to five cycles of global real-space refinement with NCS, rotamer, Ramachandran plot and C-beta deviations restraints enabled in Phenix 46 . This model was subsequently refined against the 4.3 Å map following the same real-space refinement procedure in Phenix 46 . The resulting model is identical to the 4.6 Å model, but for the addition of the first seven N-terminal residues (His1-Val7) to both receptor monomers, and contains residues His1-Asp591 and Lys691-Val720 (α -CT helix) of both of insulin receptor monomers and residues Gly1-Lys21 of chain A and Phe1-Ala30 of chain B of both bound insulins. Sugars were added to residues Asn16, Asn25, Asn111, Asn255, Asn397 and Asn418 of both insulin receptor monomers. The sugars were extracted from PDB ID 4ZXB. All subsequent, lower resolution models were generated by manually positioning the higher resolution structure onto the available density and rigid-body refining the individual domains to their final position using Coot 45 . Subsequently, the structures were subjected to five cycles of global real-space refinement with rotamer, Ramachandran plot and C-beta deviations restraints enabled in Phenix 46 . The lack of definition for the FnIII-2 and especially FnIII-3 domains may be due to the intrinsic flexibility of these regions. While one FnIII-2 region was clearly visible in the un-symmetrized map, unstructured density that could be attributed to the remaining missing regions can be seen by contouring the maps at very low sigma (Extended Data Fig. 5) . Corresponding author(s): Giovanna Scapin Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample sizes. Multiple cryoEM data sets were collected and merged to achieve the best available resolution and Euler angle orientation distribution
Data exclusions
Describe any data exclusions.
No data were excluded
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts to replication were successful 4. Randomization Describe how samples/organisms/participants were allocated into experimental groups.
Randomization is not relevant to this study,
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding is not relevant to this study, Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Test values indicating whether an effect is present
